Get started

Financials · CTMX

CytomX Therapeutics Inc. (CTMX) financials

For the twelve months ended Sep 30, 2026, CytomX Therapeutics Inc. reported $14.03M of revenue and -$85.42M of net income.

Revenue, TTM
$14.03M
Revenue growth, YoY
-87.7%
Net income, TTM
-$85.42M
Net margin
-609.0%
Free cash flow, TTM
-$51.00M
Cash
$33.96M
P/S
30.77
Market cap
$431.6M
Annual revenue$76.20M
FY2016FY2025
Annual net income-$17.37M
FY2016FY2025
Annual free cash flow-$75.81M
FY2016FY2025

CTMX revenue and earnings growth

CTMX revenueQ3 2026$1.69M

Quarter YoY
-71.7%
QoQ
+19.0%
FY YoY
-44.8%
5Y CAGR
+2.2%
10Y CAGR
+25.7%

CTMX revenue was $1.69M in fiscal Q3 2026 (ended Sep 30, 2026), down 71.7% from a year earlier and up 19.0% from the prior quarter. For the full fiscal 2025 it was $76.20M, down 44.8% from fiscal 2024. Compound annual growth was +2.2% over 5 years and +25.7% over 10 years. It rose in 6 of the last 10 fiscal years.

CTMX net incomeQ3 2026-$20.00M

CTMX net income was -$20.00M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$14.23M a year earlier. For the full fiscal 2025 it was -$17.37M, compared with $31.87M in fiscal 2024.

CTMX EPSQ3 2026-$0.09

CTMX diluted EPS was -$0.09 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$0.09 a year earlier. For the full fiscal 2025 it was -$0.15.

CTMX free cash flowQ3 2026$16.06M

CTMX free cash flow was $16.06M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$15.68M a year earlier. For the full fiscal 2025 it was -$75.81M, compared with -$86.54M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue$76.20M$138.10M$101.21M$53.16M$37.31M$68.43M$26.90M$59.50M$71.62M$15.04M
Research and development$68.73M$83.38M$77.68M$111.65M$114.19M$112.94M$131.62M$103.87M$92.28M$54.76M
Selling, general and admin$29.84M$29.73M$30.02M$42.85M$39.16M$36.03M$36.77M$33.51M$25.61M$19.87M
Operating income-$22.36M$25.00M-$6.48M-$101.33M-$116.04M-$80.54M-$141.48M-$77.87M-$46.26M-$59.59M
Interest expense---------$1.69M
Pre-tax income-$17.13M$32.09M$3.32M-$99.32M-$115.87M-$78.73M-$133.25M-$70.30M-$43.61M-$58.92M
Income tax$238.0K$224.0K$3.89M$0$0-$13.91M-$427.0K$14.30M-$513.0K-$19.0K
Net income-$17.37M$31.87M-$569.0K-$99.32M-$115.87M-$64.82M-$132.82M-$84.60M-$43.10M-$58.90M
EPS, basic-$0.15$0.38-$0.01-$1.51-$1.81-$1.40-$2.93--$1.16-$1.63
EPS, diluted-$0.15$0.38-$0.01-$1.51-$1.81-$1.40-$2.93--$1.16-$1.63
Diluted shares137.9M84.7M73.8M65.7M64.1M46.1M45.3M41.7M37.2M36.2M

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Cash and equivalents$12.67M$38.05M$17.17M$193.65M$205.53M$191.86M$188.43M$247.58M$177.55M$105.56M
Receivables$2.01M$3.10M$3.43M$35.99M$790.0K$798.0K$13.0K$97.0K$10.14M$2.16M
Current assets$143.92M$107.31M$182.94M$237.10M$310.30M$324.01M$303.33M$445.48M$388.60M$188.15M
Goodwill$949.0K$949.0K$949.0K$949.0K$949.0K$949.0K$949.0K$949.0K$949.0K$949.0K
Total assets$151.57M$120.53M$201.79M$260.89M$339.41M$358.66M$341.28M$457.11M$397.64M$199.13M
Current liabilities$46.62M$85.77M$155.91M$152.61M$77.87M$68.11M$85.59M$97.91M$61.15M$35.77M
Total liabilities$52.56M$120.99M$249.24M$346.64M$339.87M$366.44M$290.17M$326.23M$327.75M$120.65M
Shareholders' equity$99.01M-$456.0K-$47.45M-$85.75M-$459.0K-$7.77M$25.47M$135.83M$69.90M$78.48M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Operating cash flow-$75.59M-$86.23M-$56.03M-$110.79M-$119.03M$5.26M-$140.48M-$75.52M$170.37M-$2.03M
Capital expenditures$220.0K$310.0K$840.0K$1.74M$1.61M$2.31M$3.50M$3.79M$1.56M$2.18M
Free cash flow-$75.81M-$86.54M-$56.88M-$112.53M-$120.64M$2.95M-$143.98M-$79.31M$168.81M-$4.21M
Investing cash flow-$59.74M$99.70M-$150.67M$98.26M$22.49M-$18.72M$79.70M$5.93M-$121.27M$45.86M
Financing cash flow$110.45M$7.52M$30.23M$648.0K$110.21M$16.89M$1.63M$139.62M$23.80M$996.0K
Stock-based compensation$6.30M$7.67M$8.56M$13.13M$13.17M$14.79M$19.10M$16.88M$11.29M$10.10M
Depreciation and amortization-------$1.88M$1.65M$1.73M

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue growth, YoY-44.8%36.4%90.4%42.5%-45.5%154.4%-54.8%-16.9%376.1%95.1%
Operating margin-29.3%18.1%-6.4%-190.6%-311.0%-117.7%-525.9%-130.9%-64.6%-396.1%
Net margin-22.8%23.1%-0.6%-186.8%-310.5%-94.7%-493.7%-142.2%-60.2%-391.5%
Free cash flow margin-99.5%-62.7%-56.2%-211.7%-323.3%4.3%-535.2%-133.3%235.7%-28.0%
Return on equity-17.5%------521.5%-62.3%-61.7%-75.1%
Return on assets-11.5%26.4%-0.3%-38.1%-34.1%-18.1%-38.9%-18.5%-10.8%-29.6%
Current ratio3.091.251.171.553.984.763.544.556.365.26

Source: XBRL data CytomX Therapeutics Inc. files with the SEC, latest filing dated Nov 5, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

CTMX peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
CTMX$14.03M-87.7%-$85.42M-609.0%$431.6M
STRO$45.70M-56.3%-$180.64M-395.2%$168.6M
ADCT$84.87M+12.8%-$81.25M-95.7%$192.2M
IOVA$378.98M+51.3%-$220.53M-58.2%$3.74B
IMCR$429.30M+13.1%-$32.12M-7.5%$1.67B
ZYME$265.97M+97.8%$43.31M16.3%$2.22B
XNCR$200.49M+33.5%-$117.86M-58.8%$2.96B

CTMX FAQ

7 questions
  • What is CTMX revenue?
    CytomX Therapeutics Inc. (CTMX) reported $14.03M of revenue for the twelve months ended Sep 30, 2026. That is down 87.7% from the year before. Revenue for fiscal 2025 was $76.20M.
  • Is CTMX profitable?
    No. CytomX Therapeutics Inc. reported a net loss of $85.42M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does CTMX have?
    CytomX Therapeutics Inc. reported $33.96M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is CTMX revenue growing?
    CytomX Therapeutics Inc.'s revenue changed -44.8% in fiscal 2025, to $76.20M. Its compound annual growth rate was +2.2% over 5 years and +25.7% over 10 years.
  • What is CTMX free cash flow?
    CytomX Therapeutics Inc. generated -$51.00M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of -$50.21M less capital expenditures.
  • When did CTMX last report financial results?
    The latest statements here come from CytomX Therapeutics Inc.'s 10-Q filed on Nov 5, 2026, covering the period ended Sep 30, 2026.
  • Where does this CTMX financial data come from?
    Quantisnow builds these statements from the structured XBRL data CytomX Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.